# Translational Oncology

> **NIH NIH P30** · OREGON HEALTH & SCIENCE UNIVERSITY · 2021 · $4,726

## Abstract

TRANSLATIONAL ONCOLOGY- PROGRAM
Raymond Bergan, MD, and Sara A. Courtneidge, PhD, Program Co-Leaders
ABSTRACT
Translational Oncology (TO) is a multi-disciplinary program within the Knight Cancer Institute whose mission is
to improve treatments, outcomes, and quality of life for people with cancer by advancing translational science.
Members have transformed the field of translational cancer research and continue to lead by pursuing two
integrated research themes: 1) validation of high value therapeutic targets, and 2) assessing the feasibility and
efficacy of therapeutically targeting these pathways through impactful clinical investigations. Target validation is
focused on intrinsic molecular cancer abnormalities, pathways that lead to invasion and metastases, interactions
of cancer cells with the microenvironment, mechanisms of resistance to current therapies, and preclinical
evaluation or development of novel agents targeting these pathways. Projects in the second theme focus on the
development of drugs targeting tumor intrinsic molecular abnormalities, the tumor microenvironment, and
immunotherapeutics, along with studies designed to understand how best to use these agents, who responds,
why resistance occurs and means to circumvent resistance. The program is co-led by Raymond Bergan, MD,
a molecular pharmacologist whose research focuses on targeted therapy across the spectrum of carcinogenesis,
and Sara A. Courtneidge, PhD, a translational scientist whose research focuses on invadopodia and the
microenvironment. The TO Program is comprised of 52 members from 14 Departments at OHSU. Between July
2011 and March 2016, TO members produced 623 cancer-relevant publications, of which 23% represented intra-
programmatic, 25% inter-programmatic and 59% represented inter-institutional collaborative interactions. In
2015, a total of 2,019 individuals were entered on clinical studies, 700 of them interventional, 481 therapeutic.
Total funding for the program is $27,170,631, peer-reviewed funding is $10,359,011, with $3,010,767 or 29%
from NCI. Other cancer-relevant funding includes prostate and pancreatic Stand Up To Cancer Dream Team
grants, several cancer clinical trials consortia, and a Leukemia & Lymphoma Society-funded program called Beat
AML. In the current funding cycle, TO investigators had crucial roles in driving changes in FDA-approvals for 9
different agents for indications linked to improved survival in 12 cancers.

## Key facts

- **NIH application ID:** 10205362
- **Project number:** 5P30CA069533-23
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** Raymond C. Bergan
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $4,726
- **Award type:** 5
- **Project period:** 1997-08-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10205362

## Citation

> US National Institutes of Health, RePORTER application 10205362, Translational Oncology (5P30CA069533-23). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10205362. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*